The PVI Company
PVI provides an intelligence-driven platform that structures clinical, economic, and patient-centered evidence into transparent, rubric-based drug value assessments for payers. The platform builds on AMCP standards like eDossiers, PIE, and eModels to generate a baseline index and custom scenarios, updating assessments as new evidence emerges. This enables payers to evaluate drug value consistently and efficiently, freeing time for decision-making and implementation.
- Data & Analytics
- Healthcare Technology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Health plans and payers each independently assemble and interpret much of the same clinical, economic, and patient-centered evidence when assessing drug value. This fragmented, manual process is inefficient, inconsistent, and leaves limited time for actual decision-making and coverage implementation.
Solution
PVI is an evidence value intelligence platform that turns the evidence payers already receive into structured, comparable value assessments. It builds on the standards AMCP has led for 25+ years, including eDossiers, PIE, eModels, and ePosters. The platform's Evidence Intelligence Engine scores clinical, economic, and patient-centered domains on rubric-based sub-criteria calibrated with practicing payer reviewers. It generates a PVI Baseline Index, assesses manufacturer-submitted evidence separately using the same framework, and creates plan-specific custom scenarios. New evidence and market signals automatically trigger updated assessments, keeping evaluations current and transparent.
Target Audience
Primary customers are payers and health plans that need consistent, transparent, and efficient drug value assessments, as well as pharmaceutical manufacturers seeking to understand evidence gaps from the payer perspective.
Features
- Structured evidence assessment across clinical, economic, and patient-centered domains, scored on rubric-based sub-criteria calibrated with practicing payer reviewers
- PVI Baseline Index providing an independent, transparent reference point for drug value
- Manufacturer evidence impact assessment using the same framework, kept separate from the baseline index
- Custom scenario generation incorporating plan-specific inputs such as utilization data, formulary context, and payer inputs
- Continuous updating triggered by new evidence and market signals
- Integration with AMCP standards including eDossiers, PIE, eModels, and ePosters, plus published literature, FDA reviews, HTAs, and real-world evidence